Clinical Trial Update: Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for AMG 531 (Megakaryopoiesis Protein 2) in thrombocytopenic subjects with immune thrombocytopenic purpura (ITP) completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenic Purpura
• Thrombocytopenia

Drugs mentioned

• AMG 531 (AMG531)

Snippet

Sponsor: Amgen | Conditions: Thrombocytopenic Purpura | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-12-20